Large Volume Wearable Injectors have made it convenient to self-administer drugs in the home care setting, providing substantial cost benefits, improving medication adherence and reducing the risk of dosing errors, microbial contamination and needle-stick injuries; in fact,these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19).
The report features an extensive study of the current market landscape, offering an informed opinion on the likely future evolution of these self-injection devices over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
§ A detailed review of the overall landscape of large volume wearable injectors available for delivery of insulin and non-insulin drugs, in addition to the under development / available drug device combinations
§ An insightful competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power and product specifications
§ Elaborate profiles of the prominent companies that develop large volume wearable injectors.
§ An analysis of the partnerships that have been established in the period between 2015 and 2020.
§ A detailed analysis on acquisition targets.
§ An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors over the last three decades.
§ A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future
§ A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors on Twitter
§ A detailed analysis of completed, ongoing and planned clinical trials
§ A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain
§ An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval, in general.
(for delivery of non-insulin and insulin drugs)
Type of Device
§ Patch Pump / Injectors
§ Infusion Pump / Injectors
(for non-insulin drugs)
§ Neurological Disorders
§ Cardiovascular Disorders
§ Oncological Disorders
§ Infectious Disorders
Key Geographical Regions
§ North America
Key companies covered in the report:
§ Becton Dickinson
§ Bespak (subsidiary of Consort Medical)
§ Eli Lilly
§ Enable Injections
§ SOOIL Development
§ Sensile Medical (acquired by Gerresheimer)
§ SteadyMed Therapeutics (acquired by United Therapeutics)
§ Tandem Diabetes Care
§ Weibel CDS (acquired by SHL Medical)
§ West Pharmaceutical Services
For more information, please click on the following link:
Other recent offerings:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at firstname.lastname@example.org
Roots Analysis Private Limited
+1 (415) 800 3415